Amygdalin from Apricot Kernels Induces Apoptosis and Causes Cell Cycle Arrest in Cancer Cells: An Updated Review
Overview
Affiliations
Background: Amygdalin is a cyanogenic glycoside which is described as a naturally occurring anticancer agent. Current review highlights apoptosis-inducing attributes of amygdalin towards different cancers and its potential application as an anti-cancer agent in cancer therapy.
Method: Data about amygdalin was retrieved from all major scientific databases i.e., PubMed, ScienceDirect, Google Scholar, Scopus and Medline by using combination of keywords like amygdalin, apoptosis, laetrile, vitamin B- 17, pro-apoptotic proteins, anti-apoptotic proteins, hydrogen cyanide, mechanism of action of amygdalin and amygdalin therapy on humans. However, no specific time frame was followed for collection of data.
Results: Data collected from already published articles revealed that apoptosis is a central process activated by amygdalin in cancer cells. It is suggested to stimulate apoptotic process by upregulating expression of Bax (proapoptotic protein) and caspase-3 and downregulating expression of Bcl-2 (anti-apoptotic protein). It also promotes arrest of cell cycle in G0/G1 phase and decrease number of cells entering S and G2/M phases. Thus, it is proposed to enhance deceleration of cell cycle by blocking cell proliferation and growth.
Conclusion: The current review epitomizes published information and provides complete interpretations about all known anti-cancer mechanisms of amygdalin, possible role of naturally occurring amygdalin in fight against cancer and mistaken belief about cyanide toxicity causing potential of amygdalin. However, well-planned clinical trials are still needed to be conducted to prove effectiveness of this substance in vivo and to get approval for human use.
Cancer therapy by cyclin-dependent kinase inhibitors (CDKIs): bench to bedside.
Hassanzadeh A, Shomali N, Kamrani A, Soltani-Zangbar M, Nasiri H, Akbari M EXCLI J. 2024; 23:862-882.
PMID: 38983782 PMC: 11231458. DOI: 10.17179/excli2024-7076.
Ding D, Liu S, Liu F, Hao S, Zhang C, Shen Y Front Pharmacol. 2024; 15:1376037.
PMID: 38910886 PMC: 11190181. DOI: 10.3389/fphar.2024.1376037.
El-Houssiny A, Soliman A, Abdel-Nour K Discov Nano. 2024; 19(1):62.
PMID: 38573410 PMC: 10994899. DOI: 10.1186/s11671-024-03998-7.
Prajapati M, Deshmukh R, Harwansh R Curr Drug Deliv. 2023; 22(1):63-79.
PMID: 38037911 DOI: 10.2174/0115672018280381231119150732.
Spanoudaki M, Stoumpou S, Papadopoulou S, Karafyllaki D, Solovos E, Papadopoulos K Int J Mol Sci. 2023; 24(18).
PMID: 37762572 PMC: 10531689. DOI: 10.3390/ijms241814270.